<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943473</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-1867</org_study_id>
    <nct_id>NCT02943473</nct_id>
  </id_info>
  <brief_title>Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients</brief_title>
  <official_title>A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test whether the drug ibrutinib (trademark name:&#xD;
      IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who&#xD;
      currently have smoldering myeloma. The researchers conducting this trial) have reason to&#xD;
      believe that ibrutinib can delay the development of multiple myeloma, thus giving people who&#xD;
      currently have smoldering myeloma a longer period of time when they feel healthy and well.&#xD;
&#xD;
      Smoldering myeloma is an abnormal condition that is considered to be an early phase of the&#xD;
      disease multiple myeloma. In this disorder, there is an abnormal growth of plasma cells,&#xD;
      which is a type of blood cell found in the bone marrow. This growth is not as severe in&#xD;
      people with smoldering myeloma as it is in multiple myeloma, so people with smoldering&#xD;
      myeloma do not have any symptoms and tend to feel well. However, they have a higher risk of&#xD;
      developing multiple myeloma than people in the general population.&#xD;
&#xD;
      Some people with smoldering myeloma are at an especially high risk of developing myeloma -&#xD;
      50% of these people will develop multiple myeloma 2 years after they are diagnosed with&#xD;
      smoldering myeloma. The investigators identify these people by looking at the amount of&#xD;
      myeloma in the bone marrow (called &quot;bone marrow plasma cell percentage&quot;) and the amount of&#xD;
      myeloma protein (called &quot;serum protein electrophoresis&quot; and &quot;serum free light chain assay&quot;)&#xD;
      in the blood. To be considered high risk, individuals must have highly abnormal levels for&#xD;
      these tests.&#xD;
&#xD;
      Based upon current guidelines, people with smoldering myeloma do not require any treatment.&#xD;
      However, known is that many of these people will develop multiple myeloma in the near future.&#xD;
      Currently there have been no proven and effective way of preventing these people from&#xD;
      developing multiple myeloma, which remains an incurable disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, open-label, single center, prospective pilot study designed to assess the&#xD;
      efficacy of ibrutinib in subjects with high risk smoldering multiple myeloma.&#xD;
&#xD;
      All enrolled subjects will be treated with ibrutinib 560 mg (4 capsules, each containing 140&#xD;
      mg) taken PO daily for 12 cycles (28 days each). If a subject demonstrates benefit from&#xD;
      ibrutinib, therapy may be extended beyond 12 cycles to a maximum of 2 years. Subjects who&#xD;
      progress and meet criteria for symptomatic multiple myeloma will be withdrawn from study.&#xD;
&#xD;
      An initial cohort of 15 subjects will be accrued. If 4 or more patients progress to&#xD;
      symptomatic myeloma in one year, then the study will be reviewed with the FDA to determine&#xD;
      whether to employ a higher dose of ibrutinib, or to stop for futility. Otherwise, 21&#xD;
      additional patients will be accrued for a total sample size of 36.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual and risk/benefit ratio.&#xD;
  </why_stopped>
  <start_date type="Actual">May 18, 2017</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">September 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Without Symptomatic Myeloma</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Overall response rate, defined as partial response or better per IMWG criteria. (IMWG response criteria are - Complete Response, Very good partial response, partial response, Minimal response, stable disease, and progressive disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Density Changes</measure>
    <time_frame>baseline and one year</time_frame>
    <description>Changes in bone density, particularly in patients with osteopenia (defined as T-score on bone densitometry testing (DEXA) of -1 to -2.5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET-MRI Changes</measure>
    <time_frame>baseline and one year</time_frame>
    <description>Changes in PET-MRI, particularly in patients with osteopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Interleukin-6 (IL-6)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Stromal Cell-derived Factor-1 (SDF-1)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Receptor Activator of Nuclear-factor Kappa B Ligand (RANKL)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Macrophage Inflammatory Protein-1α (MIP-1α)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Dickkopf-1 (DKK-1)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum C-terminal Telopeptide (CTX)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urine N-terminal Telopeptide (NTx)</measure>
    <time_frame>baseline and up to one year</time_frame>
    <description>Bone Related Biomarker Changes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>High Risk Smoldering Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib is a type of drug called a &quot;kinase inhibitor.&quot; Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.</description>
    <arm_group_label>Ibrutinib</arm_group_label>
    <other_name>IMBRUVICA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Disease Related&#xD;
&#xD;
          1. High risk SMM, defined as follows by Mayo Clinic criteria:&#xD;
&#xD;
               1. Bone marrow plasma cells between 10% and 60%&#xD;
&#xD;
               2. Serum M-protein ≥ 3 g/dL [except IgA ≥ 2 g/dL] or urine M-protein &gt; 500 mg per 24&#xD;
                  hours&#xD;
&#xD;
               3. Serum free light chain ratio &lt; 0.126 or &gt; 8; an involved to uninvolved ratio of ≥&#xD;
                  100 is permitted&#xD;
&#xD;
               4. Measurable disease, defined as: M-protein ≥ 1 g/dL OR Bence-Jones protein (BJP) &gt;&#xD;
                  200 mg/24 hr OR involved free light chain &gt; 100 mg/dL&#xD;
&#xD;
          2. Diagnosed with SMM within the last 4 years&#xD;
&#xD;
        Laboratory&#xD;
&#xD;
          1. Adequate hematologic function independent of transfusion and growth factor support for&#xD;
             at least 7 days prior to screening, with the exception of pegylated G-CSF&#xD;
             (pegfilgrastim) and darbopoetin which require at least 14 days prior to screening&#xD;
             defined as:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 750 cells/mm3 (1.0 x 109/L).&#xD;
&#xD;
               -  Platelet count &gt; 75,000 cells/mm3 (75 x 109/L).&#xD;
&#xD;
          2. Adequate hepatic and renal function defined as:&#xD;
&#xD;
               -  Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper&#xD;
                  limit of normal (ULN).&#xD;
&#xD;
               -  Estimated creatinine clearance ≥ 30 ml/min (Cockcroft-Gault)&#xD;
&#xD;
               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of&#xD;
                  non-hepatic origin, in which case the total bilirubin should be &lt; 3 x ULN)&#xD;
&#xD;
          3. PT/INR &lt; 1.5 x ULN and PTT (aPTT) &lt; 1.5 x ULN&#xD;
&#xD;
             Demographic&#xD;
&#xD;
          4. Men and women ≥ 18 years of age&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 2&#xD;
&#xD;
        Exclusion Criteria Disease-Related&#xD;
&#xD;
          1. No end organ damage attributable to a plasma cell disorder, defined as having ANY of&#xD;
             the following:&#xD;
&#xD;
               1. Hypercalcemia: Serum calcium &gt; 1 mg/dL above the upper limit of normal or &gt; 11&#xD;
                  mg/dL&#xD;
&#xD;
               2. Renal insufficiency: Serum creatinine &gt; 2 mg/dL or creatinine clearance &lt; 30 mL&#xD;
                  per min&#xD;
&#xD;
               3. Anemia: Hemoglobin value &gt; 2 g/dL below the upper limit of normal or a hemoglobin&#xD;
                  value &lt; 10 g/dL&#xD;
&#xD;
               4. Bone lesions: One or more lytic lesions on skeletal radiography, CT, MRI, PET-CT,&#xD;
                  or PET-MRI&#xD;
&#xD;
          2. Bone marrow plasma cells &lt; 10% or &gt; 60%&#xD;
&#xD;
          3. Has received prior anti-myeloma therapy of any type&#xD;
&#xD;
          4. Has received prior bisphosphonate therapy&#xD;
&#xD;
          5. Has received an investigational drug, investigational vaccine, or has used an&#xD;
             investigational medical device within 4 weeks or 4 half-lives, whichever is longer,&#xD;
             before Cycle 1, Day 1 of study therapy&#xD;
&#xD;
          6. Osteoporosis, defined as having a T-score on DEXA of ≤ -2.5&#xD;
&#xD;
        Concurrent Conditions&#xD;
&#xD;
          1. History of other malignancies, except:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease present&#xD;
                  for ≥ 3 years before the first dose of study drug and felt to be at low risk for&#xD;
                  recurrence by treating physician&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
          2. Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc).&#xD;
             Any use of corticosteroids EITHER for &gt; 14 days OR at dosages &gt; 20 mg/day of&#xD;
             prednisone or equivalent is prohibited.&#xD;
&#xD;
          3. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug&#xD;
&#xD;
          4. Recent infection requiring systemic treatment that was completed ≤ 14 days before the&#xD;
             first dose of study drug&#xD;
&#xD;
          5. Known bleeding disorders (eg, von Willebrand's disease) or hemophilia&#xD;
&#xD;
          6. History of stroke or intracranial hemorrhage within 6 months prior to enrollment&#xD;
&#xD;
          7. Known HIV, HCV or HBV infection. Subjects who are positive for hepatitis B core&#xD;
             antibody or hepatitis B surface antigen must have a negative polymerase chain reaction&#xD;
             (PCR) result before enrollment. Those who are PCR positive will be excluded.&#xD;
&#xD;
          8. Any uncontrolled active systemic infection&#xD;
&#xD;
          9. Major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
         10. Any life-threatening illness, medical condition, or organ system dysfunction that, in&#xD;
             the investigators' opinion, could compromise the subject's safety or put the study&#xD;
             outcomes at undue risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajai Chari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <results_first_submitted>November 18, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Ajai Chari</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Smoldering multiple myeloma</keyword>
  <keyword>myeloma</keyword>
  <keyword>smoldering</keyword>
  <keyword>ibrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02943473/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled from May 2017 through June 2019</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibrutinib</title>
          <description>Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose taken PO daily for 12 cycles (28 days each).&#xD;
Ibrutinib: Ibrutinib is a type of drug called a &quot;kinase inhibitor.&quot; Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>enrolled but not dosed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibrutinib</title>
          <description>Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis&#xD;
Ibrutinib: Ibrutinib is a type of drug called a &quot;kinase inhibitor.&quot; Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Without Symptomatic Myeloma</title>
        <description>Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.</description>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib</title>
            <description>Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis&#xD;
Ibrutinib: Ibrutinib is a type of drug called a &quot;kinase inhibitor.&quot; Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Without Symptomatic Myeloma</title>
          <description>Disease response - the proportion of patients with high risk smoldering multiple myeloma who do not progress to symptomatic myeloma as defined by the IMWG.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Overall response rate, defined as partial response or better per IMWG criteria. (IMWG response criteria are - Complete Response, Very good partial response, partial response, Minimal response, stable disease, and progressive disease)</description>
        <time_frame>up to 1 year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Density Changes</title>
        <description>Changes in bone density, particularly in patients with osteopenia (defined as T-score on bone densitometry testing (DEXA) of -1 to -2.5).</description>
        <time_frame>baseline and one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PET-MRI Changes</title>
        <description>Changes in PET-MRI, particularly in patients with osteopenia</description>
        <time_frame>baseline and one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Interleukin-6 (IL-6)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Stromal Cell-derived Factor-1 (SDF-1)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Receptor Activator of Nuclear-factor Kappa B Ligand (RANKL)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Macrophage Inflammatory Protein-1α (MIP-1α)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Dickkopf-1 (DKK-1)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum C-terminal Telopeptide (CTX)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urine N-terminal Telopeptide (NTx)</title>
        <description>Bone Related Biomarker Changes</description>
        <time_frame>baseline and up to one year</time_frame>
        <posting_date>03/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibrutinib</title>
          <description>Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis&#xD;
Ibrutinib: Ibrutinib is a type of drug called a &quot;kinase inhibitor.&quot; Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tingling in Tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Left musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blateral ankle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Knee discomfort right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Right shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Groin pain right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ajai Chari</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 241-7873</phone>
      <email>ajai.chari@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

